Catalyst Pharmaceutical Partners to Present at The Roth Capital Partners 2007 New York Conference

Thursday, August 30, 2007 General News
Email Print This Page Comment bookmark
Font : A-A+

CORAL GABLES, Fla., Aug. 29 CatalystPharmaceutical Partners, Inc. (Nasdaq: CPRX) a specialty pharmaceuticalcompany that acquires or in-licenses, develops and commercializes prescriptiondrugs for the treatment of drug addiction and obsessive compulsive disorders,today announced that Patrick J. McEnany, President and Chief Executive Officer,will be presenting an overview of the Company at the Roth Capital Partners2007 New York Conference on Wednesday, September 5th at the Westin New York atTimes Square hotel in New York City. Mr. McEnany's presentation is scheduledfor 1:00pm ET.

The presentation will be webcast live and can be accessed An archived recording of the presentationwill be available for 90 days following the event.

About Catalyst Pharmaceutical Partners

Catalyst Pharmaceutical Partners, Inc. is a specialty pharmaceuticalcompany focused on the development and commercialization of prescription drugsfor the treatment of addiction and obsessive compulsive disorders. The Companyhas obtained from Brookhaven National Laboratory an exclusive worldwidelicense for nine patents and four patents pending in the United Statesrelating to the right to use vigabatrin to treat a wide variety of substanceaddictions and obsessive compulsive disorders. Catalyst has also been grantedrights to Brookhaven's vigabatrin-related foreign patents or patents pendingin more than 30 countries. The Company's initial product candidate based onvigabatrin is CPP-109. CPP-109 has been granted "Fast Track" status by the U.S.Food & Drug Administration (FDA) for the treatment of cocaine addiction. Thisindicates that the FDA has recognized that CPP-109 is intended for thetreatment of a serious or life-threatening condition for which there is noeffective treatment and which demonstrates the potential to address unmetmedical needs. Catalyst recently initiated a 180 patient randomized, double-blind, placebo-controlled, multi-center U.S. Phase II clinical trial of CPP-109 in patients with cocaine addiction and expects to initiate a similar trialin patients with methamphetamine addiction later this year.

For more information about the Company, go to

This press release contains forward-looking statements. Forward-lookingstatements involve known and unknown risks and uncertainties, which may causethe Company's actual results in future periods to differ materially fromforecasted results. A number of factors, including those factors described inthe Company's Annual Report on Form 10-K for 2006 and the Company's QuarterlyReport on Form 10-Q for the quarter ended June 30, 2007 that the Company hasfiled with the U.S. Securities and Exchange Commission ("SEC"), couldadversely affect the Company. Copies of the Company's filings with the SEC areavailable from the SEC or may be obtained upon request from the Company. TheCompany does not undertake any obligation to update the information containedherein, which speaks only as of this date.

SOURCE Catalyst Pharmaceutical Partners, Inc.

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store